(Q40277327)

19 September 2017

title

Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance (English)

1 reference

19 September 2017

1 reference

Jörn Lötsch

4

0 references

author name string

Maren Rohrbacher

series ordinal

1

1 reference

19 September 2017

Anja Kirchhof

series ordinal

2

1 reference

19 September 2017

Gerd Geisslinger

series ordinal

3

1 reference

19 September 2017

publication date

1 October 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

7

1 reference

19 September 2017

issue

7

1 reference

19 September 2017

page(s)

995-1002

1 reference

Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

A natural CYP2B6 TATA box polymorphism (-82T--> C) leading to enhanced transcription and relocation of the transcriptional start site.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Real-time DNA sequencing using detection of pyrophosphate release

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

The lowdown on linkage disequilibrium.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Baculovirus vectors: novel mammalian cell gene-delivery vehicles and their applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Functional characterization of cytochrome P450 2B6 allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.7.7.995

21 January 2018

Identifiers

DOI

10.2217/14622416.7.7.995

1 reference

19 September 2017

1 reference